Therapeutic Apheresis in Neurological Disorders
1999; Wiley; Volume: 3; Issue: 2 Linguagem: Inglês
10.1046/j.1526-0968.1999.00149.x
ISSN1526-0968
Autores Tópico(s)Complement system in diseases
ResumoTherapeutic ApheresisVolume 3, Issue 2 p. 161-171 Therapeutic Apheresis in Neurological Disorders Bhupendra Odhavji Khatri, Bhupendra Odhavji Khatri Center for Neurological Disorders, St. Francis Hospital, Milwaukee, Wisconsin, U.S.A.Search for more papers by this author Bhupendra Odhavji Khatri, Bhupendra Odhavji Khatri Center for Neurological Disorders, St. Francis Hospital, Milwaukee, Wisconsin, U.S.A.Search for more papers by this author First published: 05 January 2002 https://doi.org/10.1046/j.1526-0968.1999.00149.xCitations: 7 Dr. Khatri Center for Neurological Disorders, St. Francis Hospital, Milwaukee, Wisconsin 53215, U.S.A. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Dau PC, Lindstrom JM, Cassel CK, Denys EH, Sher EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977; 297: 1134 40. 10.1056/NEJM197711242972102 CASPubMedWeb of Science®Google Scholar 2 Arnon R, Crisp E, Kelley R, Ellison GW, Meyers LW, Tourtellotte WW. Anti-ganglioside antibodies in multiple sclerosis. J Neurol Sci 1980; 46: 179 86. 10.1016/0022-510X(80)90076-3 CASPubMedWeb of Science®Google Scholar 3 Feix JNB, Khatri B, McQuillen MP, Koethe S. Immune reactivity against membranes containing ganglioside GM1 in chronic progressive multiple sclerosis: Observation by spinal membrane immunoassay. Immunol Commun 1984; 13: 465 74. 10.3109/08820138409033893 CASPubMedWeb of Science®Google Scholar 4 Endo T, Scott DD, Stewart SS, Kundu SK, Marcus DM. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol 1984; 132: 1793 7. PubMedWeb of Science®Google Scholar 5 Paterson PY, Day ED, Whitacred CC, Berenberg RA, Harter DH. Endogenous myelin basic protein serum factors (MBP-SFs) and anti-MBP in humans: Occurrence in sera of clinically well subjects and patients with multiple sclerosis. J Neurol Sci 1981; 52: 37 51. 10.1016/0022-510X(81)90132-5 CASPubMedWeb of Science®Google Scholar 6 Garcia-Merino A, Persson MAA, Ernerudh J, Persson MA, Diaz-Gil JJ, Olsson T. Serum and cerebrospinal fluid antibodies against myelin basic protein and their IgG subclass distribution in multiple sclerosis. J Neurol Neurosurg Psych 1986; 49: 1066 70. 10.1136/jnnp.49.9.1066 CASPubMedWeb of Science®Google Scholar 7 Grundke-Iqbal I & Bornstein MB. Multiple sclerosis: Serum gamma globulin and demyelination in organ culture. Neurology 1980; 30: 749 54. 10.1212/WNL.30.7.749 CASPubMedWeb of Science®Google Scholar 8 Konat G, Offner H, Zeeberg IB. The effect of serum from multiple sclerosis patients in remission on the incubated rat brain slices. J Neurol Sci 1983; 60: 363 6. 10.1016/0022-510X(83)90146-6 CASPubMedWeb of Science®Google Scholar 9 Bradbury K, Aparicio SR, Sumner DW, Macfie A, Sagar P, Griffin NR, Bird CC. Comparison of in vitro demyelination and cytotoxicity of humoral factors in multiple sclerosis and other neurological diseases. J Neurol Sci 1985; 70: 167 81. 10.1016/0022-510X(85)90085-1 CASPubMedWeb of Science®Google Scholar 10 Schauf CL & Davis FA. Circulating toxic factors in multiple sclerosis; a perspective. Adv Neurol 1981; 31: 267 80. CASPubMedGoogle Scholar 11 Gonzales-Scarano F, Grossman RI, Galetta S, Atlas SW, Silberberg DH. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann Neurol 1987; 21: 300 6. 10.1002/ana.410210312 CASPubMedWeb of Science®Google Scholar 12 Lockwood CM. Experience with plasmapheresis in glomerulonephritis and other allergic disease. In: Dau PC, ed. Plasmapheresis and the immunobiology of myasthenia gravis. Boston: Houghton Mifflin, 1979;175–85. Google Scholar 13 Kipov DD, Dau PC, Morand P. The effect of plasmapheresis and drug immunosuppression on T-cell. Subsets as defined by monoclonal antibodies. J Clin Apheresis 1983; 1(2): 57 63. 10.1002/jca.2920010202 PubMedGoogle Scholar 14 Dau PC, Petajan JM, Johnson KP, Panitch HS, Bornstein MB. Plasmapheresis and immunosuppressive drug therapy in multiple sclerosis. Neurology 1980; 30: 1023 8. 10.1212/WNL.30.10.1023 CASPubMedWeb of Science®Google Scholar 15 Weiner HL & Dawson DM. Plasmapheresis in multiple sclerosis: Preliminary study. Neurology 1980; 30: 1029 33. 10.1212/WNL.30.10.1029 CASPubMedWeb of Science®Google Scholar 16 Khatri BO, Mcquillen MP, Koethe SM, Hussey C, Cook A. Plasmapheresis in multiple sclerosis: Correlation of clinical improvement with increased suppressor cell activity in peripheral blood. Trans Am Neurol Assoc 1980; 105: 318 20. Google Scholar 17 Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL. Intensive immunosuppression in progressive multiple sclerosis: A randomized three-arm study of high dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173 80. 10.1056/NEJM198301273080401 CASPubMedWeb of Science®Google Scholar 18 Khatri BO, Koethe SM, McQuillen MP. Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis: A pilot study. Arch Neurol 1984; 41: 734 8. 10.1001/archneur.1984.04050180056018 PubMedWeb of Science®Google Scholar 19 Tindall RSA, Walker JE, Ehle AL, Near L, Rollins J, Becker D. Plasmapheresis in multiple sclerosis: Prospective trial of pheresis and immunosuppressive versus immunosuppressive alone. Neurology 1982; 31: 739 43. 10.1212/WNL.32.7.739 Web of Science®Google Scholar 20 Weiner HL, Dau P, Birnbaum G, Feldstein M, Khatri B, Petajan J, McQuillen MP. Plasma exchange in acute multiple sclerosis: Design of a cooperative study. Arch Neurol 1983; 40: 691 2. 10.1001/archneur.1983.04050100031010 CASPubMedWeb of Science®Google Scholar 21 Guarnieri BM, Capparell R, Fratiglioni L, Inzitari D, Sita D, Amaducci L, Avanzi G, Biani D, Franco C, Lombardo R. Plasma exchange in multiple sclerosis. Int J Artif Organs 1985; 8: 215 20. CASPubMedWeb of Science®Google Scholar 22 Miller RG, Filler-Katz A, Kiprov DD. More on plasmapheresis in chronic progressive multiple sclerosis. Neurology 1985; 35: 1261. 10.1212/WNL.35.8.1261 CASPubMedWeb of Science®Google Scholar 23 Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffman RG. Chronic progressive multiple sclerosis: Double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985; 35: 312 9. 10.1212/WNL.35.3.312 PubMedWeb of Science®Google Scholar 24 Gordon PA, Carroll DJ, Etches WS, Jeffrey V, Marsh L, Morrice BL, Olmstead D, Warren KG. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Can J Neurol Sci 1985; 12: 39 44. 10.1017/S0317167100046564 CASPubMedWeb of Science®Google Scholar 25 Valbonesi M, Garelli S, Mosconi L, Zerbi D, Forlani G. Plasma exchange in the management of patients with multiple sclerosis: Preliminary observations. Vox Sang 1981; 41: 68 73. 10.1111/j.1423-0410.1981.tb01016.x CASPubMedWeb of Science®Google Scholar 26 Hocker P, Stellamor V, Summer K, Mann M. Plasma exchange (PE) and lymphocytapheresis (LCA) in multiple sclerosis (MS). Int J Artif Organs 1984; 7: 39 42. 10.1177/039139888400700107 CASPubMedWeb of Science®Google Scholar 27 Trouillas P, Neurschwander P, Tremisi JP. Modification rapide par les echanges plasmatiques de la semiologie de formes progressives de la sclerose enplaques. Rev Neurol (Paris), 1986; 142: 689 95. CASPubMedWeb of Science®Google Scholar 28 Trouillas P, Neuschwander P, Nighoghossian N. Heavy immunosuppressive treatment in progressive multiple sclerosis; a three-arm study comparing cyclophosphamide, cyclophosphamide and plasmapheresis and controls. Results after three years. In: Confavreaux C, Almard G, Devic M, eds. Trends in European multiple sclerosis research. New York: Elsevier Science Publishers, 1988:351–9. Google Scholar 29 Bystryn JC, Shenkein I, Uhr JW. A model for the regulation of antibody synthesis by serum antibody. In: Amos B, ed. Progress in immunology. New York: Academic Press, 1971:627–37. Google Scholar 30 Dau PC. Increased antibody production in peripheral blood mononuclear cells after plasma exchange therapy in multiple sclerosis. J Neuroimmunol 1995:(Nov) 62(2): 197 200. 10.1016/0165-5728(95)00121-4 CASPubMedWeb of Science®Google Scholar 31 Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL. Intensive immunosuppression in progressive multiple sclerosis. N Engl J Med 1983; 308: 173 80. 10.1056/NEJM198301273080401 CASPubMedWeb of Science®Google Scholar 32 Hommes OR, Lamers KJB, Reeker P. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 1980; 223: 177 90. 10.1007/BF00313182 PubMedWeb of Science®Google Scholar 33 Goodkin DE, Plencner S, Palmer-Saxerud J, Teetzen M, Hertsgaard D. Cyclophosphamide in chronic progressive MS: Maintenance versus non-maintenance therapy. Arch Neurol 1987; 44: 823 7. 10.1001/archneur.1987.00520200027013 CASPubMedWeb of Science®Google Scholar 34 Myers LW, Fahey JL, Moody DJ, Mickey MR, Frane MV, Ellison GW. Cyclophosphamide pulses in chronic progressive multiple sclerosis: A preliminary clinical trial. Arch Neurol 1987; 44: 828 32. 10.1001/archneur.1987.00520200032014 CASPubMedWeb of Science®Google Scholar 35 Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: Cumulative 6 year experience in 164 patients. Neurology 1988; 38(Suppl. 2): 9 14. CASPubMedWeb of Science®Google Scholar 36 Weiner HL, Dau P, Khatri BO, Petajan JH, Birnbaum G, McQuillen MP, Fosburg MT, Feldstein M, Orav EJ. Double-blind study of true versus sham plasma exchange in patients being treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989; 39: 1143 9. 10.1212/WNL.39.9.1143 PubMedWeb of Science®Google Scholar 37 The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441 6. 10.1016/0140-6736(91)93389-Q PubMedWeb of Science®Google Scholar 38 The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 345: 1096 104. 10.1212/WNL.35.8.1096 Google Scholar 39 Rodriguez M, Karnes WE, Bartleson, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993; 43: 1100 4. 10.1212/WNL.43.6.1100 PubMedWeb of Science®Google Scholar 40 Ellison GW & Myers LW. A review of systemic non-specific immunosuppressive treatment of multiple sclerosis. Neurology 1978; 28: 132 9. 10.1212/WNL.28.9_Part_2.132 CASPubMedWeb of Science®Google Scholar 41 Kaplan SR & Calabresi P. Drug therapy: Immunosuppressive agents. N Engl J Med 1973; 289: 1234 6. 10.1056/NEJM197312062892307 PubMedWeb of Science®Google Scholar 42 Likosky WH. Experience with cyclophosphamide in multiple sclerosis: The cons. Neurology 1988; 38(Suppl. 2): 14 8. CASPubMedWeb of Science®Google Scholar 43 Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Nuwer MR. Clinical experience with azathioprine: The pros. Neurology 1988; 38(Suppl. 2): 20 3. CASPubMedWeb of Science®Google Scholar 44 Silberberg DH. Azathioprine in multiple sclerosis: The cons. Neurology 1988; 38(Suppl. 2): 24 7. CASPubMedWeb of Science®Google Scholar 45 Lhermitte F, Marteau R, Roullet E, DeSaxce H, Loridan M. Long term immunosuppression in multiple sclerosis: A 15 year study with azathioprine. Rev Neurol (Paris) 1984; 140(10); 553 8. CASPubMedWeb of Science®Google Scholar 46 Kelsey JL. A review of the epidemiology of human breast cancer. Epidemiol Rev 1979; 1: 74 109. 10.1093/oxfordjournals.epirev.a036215 PubMedGoogle Scholar 47 Khatri BO, McQuillen MP, Hoffman RG, Harrington GJ, Schmoll D. Plasma exchange in chronic progressive multiple sclerosis: A long term study. Neurology 1991; 41: 409 14. 10.1212/WNL.41.3.409 PubMedWeb of Science®Google Scholar 48 Bradley E. The jacknife, the bootstrap and other resampling plans. SIAM series in applied mathematics. Philadelphia: Society for Industrial and Applied Mathematics, 1982:30. Google Scholar 49 Khatri BO, McQuillen MP, Hoffman RG. Cyclophosphamide and plasma exchange in multiple sclerosis (Letter). Lancet 1991; 337: 1033. 10.1016/0140-6736(91)92688-X PubMedWeb of Science®Google Scholar 50 Noseworthy JH, Vandervoort MK, Penman M, Ebers G, Shumak K, Selano TP, Roberts R, Yetisir E, Gent M, Taylor DW. Cyclophosphamide and plasma exchange in multiple sclerosis (Letter). Lancet 1991; 337: 1540 1. 10.1016/0140-6736(91)93226-Y CASPubMedWeb of Science®Google Scholar 51 Medenica RD, Mukerjee S, Alonso K, Lazovic G, Huschart T. Effective therapy for multiple sclerosis. J Clin Apheresis 1994; 9: 222 7. 10.1002/jca.2920090405 CASPubMedWeb of Science®Google Scholar 52 Dau PC. Plasmapheresis in acute multiple sclerosis: Rationale and results. J Clin Apheresis 1991; 6: 200 4. 10.1002/jca.2920060405 CASPubMedGoogle Scholar 53 Medenica RD, Mukerjee S, Huschart T, Corbitt W. Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis. J Clin Apheresis 1994; 9: 216 21. 10.1002/jca.2920090404 CASPubMedWeb of Science®Google Scholar 54 Interferon beta (IFNB) Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, 1: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655 61. 10.1212/WNL.43.4.655 PubMedWeb of Science®Google Scholar 55 Ciavarella D, Wuest D, Strauss RG, Gilcher RO, Kasprisin DO, Kiprov DD, Klein HG, McLeod BC. Management of neurological disorders. J Clin Apheresis 1993; 8: 242 57. 10.1002/jca.2920080406 CASPubMedGoogle Scholar 56 Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978; 2: 1100. 10.1016/S0140-6736(78)91837-8 PubMedWeb of Science®Google Scholar 57 Cook JD, Tindall RAS, Walker J, Khan A, Rosenberg R. Plasma exchange as a treatment of acute and chronic idiopathic autoimmune polyneuropathy: Limited success. Neurology 1980; 30: 361 2. Web of Science®Google Scholar 58 Schooneman F, Janot C, Streiff F, Gerard A, Dureux JB, Canton P, Roche G, Aubrun P. Plasma exchange in Guillain-Barré syndrome: Ten cases. Plasma Ther 1981; 2: 117 21. Google Scholar 59 Valbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I. Plasma exchange as a therapy for Guillain-Barré syndrome with immune complexes. Vox Sang 1981; 41: 74 8. 10.1111/j.1423-0410.1981.tb01017.x CASPubMedWeb of Science®Google Scholar 60 De Jager AEJ, The TH, Smit Sibinga CTS, Das PC. Plasma exchange in the Guillain-Barré syndrome. Br Med J 1981; 283: 794 5. 10.1136/bmj.283.6294.794-c PubMedWeb of Science®Google Scholar 61 Rumpl E, Mayr U, Gerstenbrand F, Hackl JM, Rosmanith P, Aichner F. Treatment of Guillain-Barré syndrome by plasma exchange. J Neurol 1981; 225: 207 17. 10.1007/BF00313750 CASPubMedWeb of Science®Google Scholar 62 Osterman PO, Lundemo G, Pirskanen R, Fagius J, Pihlstedt P, Siden A, Safwenberg J. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2: 1296 9. 10.1016/S0140-6736(84)90819-5 PubMedWeb of Science®Google Scholar 63 Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096 1104. 10.1212/WNL.35.8.1096 PubMedWeb of Science®Google Scholar 64 French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: Role of replacement fluids. Ann Neurol 1987; 22: 753 61. 10.1002/ana.410220612 PubMedWeb of Science®Google Scholar 65 Schaumburg HH. Inflammatory polyneuropathy (Guillain-Barré syndrome and related disorders). In: Wyngaarden JB, Smith LH, eds. Cecil textbook of medicine. Philadelphia: WB Saunders, 1988:2260–2. Google Scholar 66 Morris JH. The peripheral nervous system. In Cotran RS, Kumar reat V, Robbins SL, eds. Robbins pathologic basis of disease. Philadelphia: WB Saunders, 1989:1444–5. Google Scholar 67 McKhann GM. Guillain-Barré syndrome: Clinical and therapeutic observation. Ann Neurol 1990; 27(Suppl.): 513 6. PubMedWeb of Science®Google Scholar 68 Asbury AK & Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27(Suppl.): 521 4. Google Scholar 69 Greenwood RJ, Hughes RAC, Bowden AN, Gordon NS, Millac P, Newsom-Davis J, Aslan S, Chadwick DW, McLellan DL, Stott RB, Armitage P. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 1: 877 9. 10.1016/S0140-6736(84)91341-2 PubMedWeb of Science®Google Scholar 70 Weinstein R. Is there a scientific rationale for therapeutic plasma exchange or intravenous immune globulin in the treatment of acute Guillain-Barré syndrome? J Clin Apheresis 1995; 10: 150 7. 10.1002/jca.2920100310 CASPubMedWeb of Science®Google Scholar 71 Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225 30. PubMedWeb of Science®Google Scholar 72 Hughes RAC, Neusom-Davis JM, Perkins UD. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2: 750. 10.1016/S0140-6736(78)92644-2 PubMedWeb of Science®Google Scholar 73 Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory demyelinating polyradiculopathy. Mayo Clin Proc 1975; 50: 621 37. PubMedWeb of Science®Google Scholar 74 Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculopathy. N Engl J Med 1986; 314: 461 5. 10.1056/NEJM198602203140801 PubMedWeb of Science®Google Scholar 75 Dyck PJ, O'Brien PC, Ovian KF, Dinapoli RP, Daube JR, Bartleson JD, Mokri B, Swift T, Low PA, Windebank AJ. Prednisone improves chronic inflammatory demyelinating polyradiculopathy more than no treatment. Ann Neurol 1982; 11: 136 41. 10.1002/ana.410110205 CASPubMedWeb of Science®Google Scholar 76 Choudhary PP & Hughes RA. Long-term treatment of chronic inflammatory demyelinating polyradiculopathy with plasma exchange or intravenous gammaglobulin. QJM 1995; 88: 493 502. PubMedWeb of Science®Google Scholar 77 Khatri BO & Wroblewski M. Plasma exchange in chronic inflammatory demyelinating polyneuropathy. A long term experience (Abstract). J Clin Apheresis 1995; 10(1): 40. Google Scholar 78 Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC. A plasma exchange versus immunoglobulin infusion trial in chronic inflammatory demyelinating polyradiculopathy. Ann Neurol 1994; 36: 838 45. 10.1002/ana.410360607 PubMedWeb of Science®Google Scholar 79 Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy. Clinical features and response to treatment in 67 consecutive patients with and without amonoclonal gammopathy. Neurology 1997; 48: 321 8. Google Scholar 80 Yi Q & Letvert AK. Current and future therapies for myasthenia gravis. Drugs Aging 1997; 11(2): 132 9. 10.2165/00002512-199711020-00005 CASPubMedWeb of Science®Google Scholar 81 Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: Investigation by plasma exchange. Neurology 1978; 28: 266 72. 10.1212/WNL.28.3.266 CASPubMedWeb of Science®Google Scholar 82 Seybold ME. Plasmapheresis in myasthenia gravis. Ann NY Acad Sci 1987; 505: 584 7. 10.1111/j.1749-6632.1987.tb51326.x CASPubMedWeb of Science®Google Scholar 83 Dau PC. Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients. Ann NY Acad Sci 1981; 377: 700 8. 10.1111/j.1749-6632.1981.tb33768.x PubMedWeb of Science®Google Scholar 84 D'Empaire G, Hoaglin DC, Perlo VP, Pontoppidan H. Effect of prethymectomy plasma exchange on postoperative respiratory function in myasthenia gravis. J Thorac Cardiovasc Surg 1985; 89: 592 6. CASPubMedWeb of Science®Google Scholar 85 Pinching AJ, Peters DK, Newsom-Davis JN. Remission of myasthenia gravis following plasma exchange. Lancet 1976; 2: 1373 6. 10.1016/S0140-6736(76)91917-6 CASPubMedWeb of Science®Google Scholar 86 Lisak RP, Abramsky O, Schotland DL. Plasmapheresis in the treatment of myasthenia gravis: Preliminary study in 21 patients. In: Dau PC, ed. Plasmapheresis and the immunobiology of myasthenia gravis. Boston: Houghton Mifflin, 1979:209–15. Google Scholar 87 Newsom-Davis J, Vincent A, Wilson SG, Ward CD. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979; 1: 464 8. 10.1016/S0140-6736(79)90823-7 CASPubMedWeb of Science®Google Scholar 88 Khatri BO & Wroblewski M. Long term plasma exchange therapy in myasthenia gravis patients (Abstract). J Clin Apheresis 1995; 10(1): 40. Google Scholar 89 Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical trial of cyclosporin in myasthenia gravis. Ann NY Acad Sci 1993; 681: 539 51. 10.1111/j.1749-6632.1993.tb22937.x PubMedWeb of Science®Google Scholar 90 Gajdas P, Outin H, Elkharrat D, Brunel D, DeRohan-Chabot P, Raphael JC, Goulon M, Goulon-Goead C, Morel E. High dose intravenous gamma globulin for myasthenia gravis. Lancet 1984; 1: 406 7. 10.1016/S0140-6736(84)90469-0 Google Scholar 91 Fatek-Moghadam A, Wick M, Besinger V, Geursen RG. High dose intravenous gamma globulin for myasthenia gravis. Lancet 1984; 7: 848. 10.1016/S0140-6736(84)92294-3 Google Scholar 92 Poltz PH, Dalakas M, Leff RL, Love LA, Miller FW, Cronin ME. Current concepts in the idiopathic inflammatory myopathies: Polymyositis, dermatomyositis and related disorders. Ann Intern Med 1989; 111: 143 7. 10.7326/0003-4819-111-2-143 PubMedWeb of Science®Google Scholar 93 Cherin P, Herson S, Godeau P. Treatment of polymyositis and dermatomyositis. Eur J Intern Med 1992; 3: 189 96. Google Scholar 94 Dau PC. Plasmapheresis in idiopathic inflammatory myopathy. Arch Neurol 1981; 38: 544 52. 10.1001/archneur.1981.00510090038003 CASPubMedWeb of Science®Google Scholar 95 Khatri BO, Luprecht G, Weiss SA. Plasmapheresis and immunosuppressive drug therapy in polymyositis. Muscle Nerve 1982; 5: 568 9. 10.1002/mus.880050710 CASPubMedWeb of Science®Google Scholar 96 Cecere FA & Spiva DA. Combination plasmapheresis/leukocytapheresis for the treatment of dermatomyositis/polymyositis. Plasma Ther Transfus Technol 1982; 3: 401 9. Web of Science®Google Scholar 97 Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, Fraser DD, Dalakas M, Plotz PH. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326: 1380 4. 10.1056/NEJM199205213262102 PubMedWeb of Science®Google Scholar 98 Cherin P, Auperin I, Bussel A, Pourrat J, Herson S. Plasma exchange in polymyositis and dermatomyositis: A multicenter study of 57 cases (Letter). Clin Exp Rheumatol 1995; 13(2): 270 1. PubMedWeb of Science®Google Scholar 99 Jablecki C. Lambert-Eaton myasthenic syndrome. Muscle Nerve 1984; 7: 250 7. 10.1002/mus.880070311 CASPubMedWeb of Science®Google Scholar 100 Newsom-David J. Lambert-Eaton myasthenic syndrome. Semin Immunopathol 1985; 8: 129 40. Web of Science®Google Scholar 101 Lang B, Newson-Davis J, Wray D, Vincent A. Autoimmune activity for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2: 224 6. 10.1016/S0140-6736(81)90474-8 CASPubMedWeb of Science®Google Scholar 102 Lennon VA, Lambert EH, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982; 5: 521 5. Web of Science®Google Scholar 103 Hughes RL & Katirji MG. The Eaton-Lambert (myasthenic) syndrome in association with systemic lupus erythematosus. Arch Neurol 1986; 43: 1186 7. 10.1001/archneur.1986.00520110072020 CASPubMedWeb of Science®Google Scholar 104 Lindstrom J. Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome. Ann Rev Immunol 1985; 3: 109 31. 10.1146/annurev.iy.03.040185.000545 CASPubMedWeb of Science®Google Scholar 105 Ingram DA, Davis GR, Schwartz MS, Traub M, Newland AC, Swash M. Cancer-associated myasthenic (Eaton-Lambert) syndrome: Distribution of abnormality and effect of treatment. J Neurol Neurosurg Psych 1984; 47: 806 12. 10.1136/jnnp.47.8.806 CASPubMedWeb of Science®Google Scholar 106 Rooks ED, Eaton LM, Lambert EH. Myasthenia and malignant intrathoracic tumor. Med Clin North Am 1960; 44: 977 88. 10.1016/S0025-7125(16)33984-0 PubMedWeb of Science®Google Scholar 107 Denys EH, Dau PC, Lindstrom JM. Neuromuscular transmission before and after plasmapheresis in myasthenia gravis and themyasthenic syndrome. In: Dau PC, ed. Plasmapheresis and the immunobiology of myasthenia gravis. Boston: Houghton Mifflin, 1979:248–57. Google Scholar 108 Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune etiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981; 2: 224 6. 10.1016/S0140-6736(81)90474-8 CASPubMedWeb of Science®Google Scholar 109 Dau PC & Denys EH. Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982; 11: 570 5. 10.1002/ana.410110604 CASPubMedWeb of Science®Google Scholar 110 Anderson NE, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration: Clinical-immunologic correlations. Ann Neurol 1988; 24: 559 67. 10.1002/ana.410240413 PubMedWeb of Science®Google Scholar 111 Anderson NE, Rosenblum MK, Graus F, Wiley RG, Posner JB. Autoantibodies in paraneoplastic syndromes associated with small cell lung cancer. Neurology 1988; 38: 1391 8. 10.1212/WNL.38.9.1391 PubMedWeb of Science®Google Scholar 112 Graus F, Elkon KB, Cordon-Cardo C, Posner JB. Sensory neuronopathy and small cell lung cancer: An antineuronal antibody that also reacts with tumor. Am J Med 1986; 80: 45 52. 10.1016/0002-9343(86)90047-1 CASPubMedWeb of Science®Google Scholar 113 Greenlee JE & Brashear HR. Antibodies to cerebellar Purkinje cells in patients with cerebellar degeneration and ovarian carcinoma. Ann Neurol 1983; 14: 609 13. 10.1002/ana.410140603 CASPubMedWeb of Science®Google Scholar 114 Furneaux HM, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 1990; 40: 1085 91. 10.1212/WNL.40.7.1085 PubMedWeb of Science®Google Scholar 115 Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer - A quantitative Western blot analysis. Ann Neurol 1990; 27: 544 52. 10.1002/ana.410270515 PubMedWeb of Science®Google Scholar 116 Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold Jr SC, Glantz MJ, Jaeckle RA, Biran H, Lesser M, et al. Anti-Ri An antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991; 29: 241 51. 10.1002/ana.410290303 CASPubMedWeb of Science®Google Scholar 117 Posner JB. Paraneoplastic cerebellar degeneration. In: DeVita VT, Hellman S, Rosenberg SA, eds. PPO updates. Philadelphia: J.B. Lippincott, 1991;Vol. 5, No. 11:1–7. Google Scholar 118 Graus F, Ribalta T, Campo E, Monforte R, Urbano A, Rozman C. Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis. Neurology 1990; 40: 219 22. 10.1212/WNL.40.2.219 PubMedWeb of Science®Google Scholar 119 Rosenblum MK. Paraneoplasia and autoimmunologic injury of the nervous system: The anti-Hu syndrome. Brain Pathol 1993; 3: 199 12. 10.1111/j.1750-3639.1993.tb00747.x CASPubMedWeb of Science®Google Scholar 120 Jean WC, Dalmau J, Ho A, Posner JB. Analsysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu associated paraneoplastic encephalomyelitis. Neurology 1994; 44: 140 7. 10.1212/WNL.44.1.140 CASPubMedWeb of Science®Google Scholar 121 Dalmau J, Graus F, Cheung NK, Rosenblum MK, Ho A, Canete A, Delattre JY, Thompson SJ, Posner JB. Major histocompatibility proteins, anti-Hu antibodies and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 1995; 75: 99 09. 10.1002/1097-0142(19950101)75:1 3.0.CO;2-I CASPubMedWeb of Science®Google Scholar 122 Voltz R, Dalmau J, Posner J, Rosenfeld M. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 1998; 51: 1146 50. 10.1212/WNL.51.4.1146 CASPubMedWeb of Science®Google Scholar 123 Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuropathy. A clinical study of 71 patients. Medicine 1992; 71: 59 72. 10.1097/00005792-199203000-00001 CASPubMedWeb of Science®Google Scholar 124 Tsukamoto T, Yoshie O, Tada K, Iwasaki Y. Anti-Purkinje cell antibody producing B-cell lines from a patient with paraneoplastic cerebellar degeneration. Arch Neurol 1987; 111: 833 7. 10.1001/archneur.1987.00520200037015 Google Scholar 125 Cocconi G, Ceci G, Juvarra G, Minopoli MR, Cocchi T, Fiaccadori F, Lechi A, Boni P. Successful treatment of subacute cerebellar degeneration in ovarian carcinoma with plasmapheresis. Cancer 1985; 56: 2318. 10.1002/1097-0142(19851101)56:9 3.0.CO;2-9 CASPubMedWeb of Science®Google Scholar 126 Graus F, Abos J, Roquer J, Mazzara R, Pereira A. Effect of plasmapheresis on stem and CSF antoantibody levels in CNS paraneoplastic syndromes. Neurology 1990; 40: 1621 3. 10.1212/WNL.40.10.1621 CASPubMedWeb of Science®Google Scholar 127 Graus F, Vega F, Delattre JY, Bonaventure I, Rene R, Arbaiza D, Tolosa E. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 1992; 42: 536 40. 10.1212/WNL.42.3.536 CASPubMedWeb of Science®Google Scholar Citing Literature Volume3, Issue2May 1999Pages 161-171 ReferencesRelatedInformation
Referência(s)